Verona Pharma plc is a clinical-stage biopharmaceutical company focusing on the development of therapeutics for respiratory conditions with unmet medical needs. The company's primary objective is to c... Verona Pharma plc is a clinical-stage biopharmaceutical company focusing on the development of therapeutics for respiratory conditions with unmet medical needs. The company's primary objective is to create innovative drugs for diseases such as chronic obstructive pulmonary disease (COPD) and asthma, which significantly affect patients worldwide. A key asset in Verona Pharma's portfolio is ensifentrine, a dual inhibitor of the enzymes phosphodiesterase 3 and 4, designed to deliver bronchodilation and anti-inflammatory effects through inhalation. This novel mechanism is intended to address both the symptoms and underlying inflammation associated with respiratory disorders. Verona Pharma plc plays a crucial role in the healthcare sector, particularly in the specialty pharmaceuticals market, by exploring therapies that could offer alternative or supplementary options to existing treatment regimes. With its commitment to advancing respiratory medicine, Verona Pharma is positioned as a pivotal player in improving patient outcomes for chronic respiratory diseases.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Verona Pharma is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Verona Pharma is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Verona Pharma's data?

Start your 30-day free trial to request a data review for Verona Pharma.

Start Free Trial

Legal Center Contact Us